Results 101 to 110 of about 52,757 (299)

Avaliação dos resultados tardios da ressecção transuretral na hiperplasia prostática benigna. [PDF]

, 2007
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Belli, Marcelo
core  

Magnitude and factors associated with benign prostatic hyperplasia among adult male patients visiting Wolaita Sodo University comprehensive specialized hospital southern Ethiopia

Scientific Reports
Worldwide, in Africa and Ethiopia prevalence of Benign Prostatic Hyperplasia among patients with lower urinary tract symptoms was 26.2%, 44.2%, and 33.4% respectively.
Tirufat Tiruneh, Tamiru Getachew, Firdawek Getahun, Tesfaye Gebreyesus, Simeon Meskele   +4 more
doaj   +1 more source

Procaspase- 3 Status in Benign Prostatic Hyperplasia and Carcinoma (A Correlative Retrospective Study)

مجلة كلية الطب, 2009
Background: Benign prostatic hyperplasia and prostatic adenocarcinoma are two of the most common pathologic mass lesions. Both are encountered mainly in elderly males. The caspases family is a group of at least 15 known proteases that serve as initiator &
Alaa A. Qader, Nabeel W. Rasheed
doaj   +1 more source

A Simple Cell Culture Assay for Human Prostatic Branching Morphogenesis Spotlights Bone Morphogenetic Protein Signaling as a Therapeutic Target in Benign Prostatic Hyperplasia

The Prostate, EarlyView.
ABSTRACT Background Benign prostatic hyperplasia (BPH) leads to prostate enlargement and lower urinary tract symptoms that can resist treatment. A histologic hallmark of BPH is glandular epithelial hyperplasia with new ductal branching morphogenesis. The stromal inductive factors driving tissue morphogenesis may provide new therapeutic targets, but are
Anna S. Pollack, James D. Brooks, Jonathan R. Pollack   +2 more
wiley   +1 more source

Prostate blood flow in patients with benign prostatic hyperplasia complicated by urine retention

RUDN Journal of Medicine, 2012
Benign prostatic hyperplasia is the most frequent disease among middle and old aged men and connected with increasing of lifetime of men. The incidence of the disease is 42% to 87% in different aged groups.
E A Atamanova, V P Avdoshin, M I Andryukhin, V V Chugaev   +3 more
doaj  

Frequency and Trends of Prostatic Diseases in a Subset of Karachi Population: A Retrospective Study

Pakistan Journal of Medicine and Dentistry
Background: Prostatic diseases are a leading cause of frequent urinary complaints in elderly males. The most common diseases include prostatitis, benign prostatic hyperplasia, and prostate cancer.
Asma Shabbir, Umaima Tariq Khan, Diya Nasir, Parvesh Kumar Rath, Cheena Kumari, Talat Zehra, Syed Mehmood Hasan   +6 more
doaj   +1 more source

Evaluation of Potential Hormonal Activities of Ashwagandha (Withania somnifera)

Phytotherapy Research, EarlyView.
ABSTRACT Ashwagandha is a widely used herb in traditional medicine systems, particularly Ayurveda. Despite its extensive tradition, growing concerns regarding its potential endocrinological effects have prompted scientific scrutiny. This review systematically evaluates the current preclinical, clinical, and case study evidence concerning AS's effects ...
Günter Vollmer, Thomas Brendler
wiley   +1 more source

Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability [PDF]

, 2014
Hee Ju Cho, Tag Keun Yoo Department of Urology, Eulji Hospital, Eulji University School of Medicine, Seoul, KoreaAbstract: α1-Adrenergic receptor antagonists are commonly used to treat male lower urinary tract symptoms and benign prostatic ...
Yoo TK, Cho HJ
core  

Benign prostatic hyperplasia and periodontitis [PDF]

Benign prostatic hyperplasia and periodontitis are common chronic diseases in middle-aged and elderly people, with many common risk factors and pathogenesis.
HOU Junqing, YANG Shisong, QIAN Xinhang, ZHU Cong, FANG Cheng   +4 more
core   +1 more source

Safety Evaluation of an Aqueous Root and Leaf Extract of Ashwagandha (Withania somnifera)

Phytotherapy Research, EarlyView.
Sensoril, an aqueous root and leaf extract of ashwagandha showed no evidence of mutagenicity in the in vitro Ames assay, was negative in the in vitro micronucleus, in vivo mammalian bone marrow chromosome aberration assays, and was well tolerated in the rat at up to 4000 mg/kg BW/day when administered orally for a period of 90 days. The data from these
Mukesh Summan, Candace L. Doepker, Gregory P. Brorby   +2 more
wiley   +1 more source